A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
PD-1
non-small-cell lung cancer
phase I
sasanlimab
urothelial carcinoma
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
14
12
2022
revised:
15
05
2023
accepted:
23
05
2023
medline:
29
8
2023
pubmed:
30
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Sasanlimab is an antibody to the programmed cell death protein 1 receptor. We report updated data of subcutaneous sasanlimab in non-small-cell lung cancer (NSCLC) and urothelial carcinoma dose expansion cohorts from a first-in-human phase Ib/II study. Patients were ≥18 years of age with NSCLC or urothelial carcinoma, and no prior immunotherapies, who progressed on or were intolerant to systemic therapy, or for whom systemic therapy was refused or unavailable. Patients received subcutaneous sasanlimab at 300 mg every 4 weeks (q4w). Primary objectives were to evaluate safety, tolerability, and clinical efficacy by objective response rate (ORR). Sixty-eight and 38 patients with NSCLC and urothelial carcinoma, respectively, received subcutaneous sasanlimab. Overall, sasanlimab was well tolerated; 13.2% of patients experienced grade ≥3 treatment-related adverse events. Confirmed ORR was 16.4% and 18.4% in the NSCLC and urothelial carcinoma cohorts, respectively. ORR was generally higher in patients with high programmed death-ligand 1 (PD-L1) expression (≥25%) and high tumor mutational burden (TMB; >75%). In the NSCLC and urothelial carcinoma cohorts, median progression-free survival (PFS) was 3.7 and 2.9 months, respectively; corresponding median overall survival (OS) was 14.7 and 10.9 months. Overall, longer median PFS and OS correlated with high PD-L1 expression and high TMB. Longer median PFS and OS were also associated with T-cell inflamed gene signature in the urothelial carcinoma cohort. Subcutaneous sasanlimab at 300 mg q4w was well tolerated with promising clinical efficacy observed. Phase II and III clinical trials of sasanlimab are ongoing to validate clinical benefit. Subcutaneous sasanlimab may be a potential treatment option for patients with NSCLC or urothelial carcinoma.
Sections du résumé
BACKGROUND
Sasanlimab is an antibody to the programmed cell death protein 1 receptor. We report updated data of subcutaneous sasanlimab in non-small-cell lung cancer (NSCLC) and urothelial carcinoma dose expansion cohorts from a first-in-human phase Ib/II study.
PATIENTS AND METHODS
Patients were ≥18 years of age with NSCLC or urothelial carcinoma, and no prior immunotherapies, who progressed on or were intolerant to systemic therapy, or for whom systemic therapy was refused or unavailable. Patients received subcutaneous sasanlimab at 300 mg every 4 weeks (q4w). Primary objectives were to evaluate safety, tolerability, and clinical efficacy by objective response rate (ORR).
RESULTS
Sixty-eight and 38 patients with NSCLC and urothelial carcinoma, respectively, received subcutaneous sasanlimab. Overall, sasanlimab was well tolerated; 13.2% of patients experienced grade ≥3 treatment-related adverse events. Confirmed ORR was 16.4% and 18.4% in the NSCLC and urothelial carcinoma cohorts, respectively. ORR was generally higher in patients with high programmed death-ligand 1 (PD-L1) expression (≥25%) and high tumor mutational burden (TMB; >75%). In the NSCLC and urothelial carcinoma cohorts, median progression-free survival (PFS) was 3.7 and 2.9 months, respectively; corresponding median overall survival (OS) was 14.7 and 10.9 months. Overall, longer median PFS and OS correlated with high PD-L1 expression and high TMB. Longer median PFS and OS were also associated with T-cell inflamed gene signature in the urothelial carcinoma cohort.
CONCLUSIONS
Subcutaneous sasanlimab at 300 mg q4w was well tolerated with promising clinical efficacy observed. Phase II and III clinical trials of sasanlimab are ongoing to validate clinical benefit. Subcutaneous sasanlimab may be a potential treatment option for patients with NSCLC or urothelial carcinoma.
Identifiants
pubmed: 37385154
pii: S2059-7029(23)00823-2
doi: 10.1016/j.esmoop.2023.101589
pmc: PMC10485400
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101589Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Nat Med. 2021 Dec;27(12):2200-2211
pubmed: 34893775
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Lancet Oncol. 2013 Sep;14(10):962-70
pubmed: 23965225
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Mol Cancer Ther. 2020 Oct;19(10):2105-2116
pubmed: 32847983
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet Oncol. 2018 Nov;19(11):1468-1479
pubmed: 30262187
J Mol Diagn. 2021 Sep;23(9):1159-1173
pubmed: 34197924
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
JAMA Oncol. 2019 Jul 01;5(7):999-1007
pubmed: 31145415
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Oncologist. 2021 Oct;26(10):e1786-e1799
pubmed: 34196068
Ann Oncol. 2017 Apr 1;28(4):836-842
pubmed: 28031173
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Lancet Oncol. 2021 Jul;22(7):931-945
pubmed: 34051178
Target Oncol. 2021 Nov;16(6):773-787
pubmed: 34694529
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Future Oncol. 2019 Oct;15(28):3267-3281
pubmed: 31394933
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097